The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Web-Based Clinical Assessment, 2008Developing and Validating Web-based Clinical Assessments for Parkinson's Disease
Objective/Rationale:
Parkinson's disease clinical research traditionally relies on patient recruitment, which can be hindered by the amount of travel a patient must undertake to visit sites for... -
MJFF Research Grant, 2008Validation of Neuroimaging Biomarkers for Nigrostriatal Neurons
Objective/Rationale:
No treatment has been proven to slow progression of Parkinson's disease. To develop such a treatment requires an objective measure of disease progression. Current clinically based... -
Therapeutics Development Initiative, 2008Cerebrospinal Fluid Biomarkers of Microtubule-mediated Axonal Transport for Monitoring of Disease Progression and Therapeutic Interventions in Parkinson's Disease
Objective/Rationale:
Techniques for measuring in humans the activity of brain chemical pathways that are fundamentally involved in the initiation, progression or reversal of Parkinson’s disease would... -
Therapeutics Development Initiative, 2008Selective Inhibition of Cyclic Nucleotide Phosphodiesterase Type 7 (PDE7): A Novel and Efficacious Approach to Treating Parkinson's Disease
Objective/Rationale:
Levodopa is the gold standard treatment for Parkinson’s disease. However, its continued use results in serious side effects including abnormal involuntary movements, or... -
Therapeutics Development Initiative, 2008Development of ERb agonists for the treatment of Parkinson's Disease
Objective/Rationale:
Estrogens modulate many cerebral functions such as mental state, mood, cognition and locomotion. Data indicate that estrogens may slow down the development and progression of PD... -
Therapeutics Development Initiative, 2008Multiphosphatase Inhibitors as PD Therapeutics
Objective/Rationale:
Parkinson’s disease has multiple genetic and environmental causes. As a result, therapeutic efforts aimed at a single cause of the disease may have limited value. ShanaRx has...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.